Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

IRB16-128
Cancer - Melanoma
John McCann, MD
D'amour Center for Cancer Care
3350 Main Street
Springfield MA 01199
The purpose of this study is to compare the effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) to the usual treatment of either interferon alfa-2b or ipilimumab.  In this study, you will get either MK-3475 or a choice of either interferon alfa-2b or ipilimumab. 
High risk Resected Melanoma
Betsy Lopez
413-794-4154